Selective suppression of vasodilator and platelet inhibitory prostaglandins without blocking the vasoconstrictive and platelet-activating prostaglandins by COX-2 inhibitors can enhance the risk of hypertension, atherosclerosis, or even thrombosis87–90. The gene discussed is PTGS2; the disease is atherosclerosis.